Compare Freeport-McMoRan Inc (FCX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Freeport-McMoRan Inc trades at $69.17 (market cap $98.71B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Freeport-McMoRan Inc pays a 0.85% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FCX | VRTX | |
|---|---|---|
Market Cap | $98.71B | $132.79B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $529.65 |
52-Week Low | $35.34 | $376.62 |
Enterprise Value | $104.99B | $126.92B |
Dividend Yield | 0.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.62, up 2.1% today, with a bullish technical signal from moving averages but overbought RSI near 86. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.68 above the $0.60 forecast. Revenue reached $25.92B in 2025, with net income margin improving to 8.5%. Recent news highlights progress at the Grasberg mine and strong copper prices supporting operations.
Outlook is positive with a consensus price target of $73.85, implying 6% upside, backed by 61% analyst buy ratings. Risks include reliance on commodity cycles and potential volatility from economic shifts. The company's solid cash flow and debt reduction trend provide stability, but investors should monitor copper market dynamics for sustained growth.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
